Carl Rosen, MD
Ophthalmology · Anchorage, AKNPI 1306839873
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $3,000 of the $3,873 with a category attached, or 77.5%. Amgen accounts for 78.7% of it on its own, with 8 other manufacturers making up the rest. Reporting peaked in 2022 at $3,110 and has fallen 96.6% since, to $105 in 2025.
Across 43 payments — averaging $90.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$3K
- AbbVie$330
- Alcon$311
- AstraZeneca$44
- Genentech USA, Inc.$34
- Bausch & Lomb, A Division Of Bausch Health US, LLC$34
- plus $71 from 3 others
What the payments were for
- Speaking & faculty fees$3,00077%
- Food & beverage$87323%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 8 | $3,049 |
| AbbVie(2 entities) | 19 | $330 |
| Alcon | 8 | $311 |
| AstraZeneca | 2 | $44 |
| Genentech USA, Inc. | 1 | $34 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 2 | $34 |
| Oyster Point Pharma, Inc. | 1 | $29 |
| Alimera Sciences, Inc. | 1 | $24 |
| Novartis | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TEPEZZA$3,000
How this compares
$3,873 in reported general payments places this provider in the 85th percentile of 30 ophthalmology providers in Alaska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ErythromycinErythromycin Base | 165 | $2,960 |
| Tobramycin-DexamethasoneTobramycin/Dexamethasone | 24 | $1,564 |
| Latanoprost | 30 | $602 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 11 | $210 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Anchorage
- Eric CoulterAnchorage$7K
- Elizabeth MorganAnchorage$3K
- Don DavisAnchorage$3K
- Eileen MyersAnchorage$2K
- Scott LimstromAnchorage$2K
- Kelly LorenzAnchorage$2K
- Griffith SteinerAnchorage$747
- David ZumbroAnchorage$429
- David ChamberlainAnchorage$408
- James FordAnchorage$373
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.